Miscellaneous respiratory disorders:
Indications for BRONCHITOL:
As add-on maintenance therapy to improve pulmonary function in adults with cystic fibrosis. Use only in those who have passed the Bronchitol Tolerance Test (BTT).
Must perform the BTT and evaluate response prior to prescribing. Administer an orally inhaled, short-acting bronchodilator 5–15mins prior to each dose. 400mg twice daily by oral inhalation (contents of 10 caps administered individually) via the inhaler. Take in the AM and PM (with the later dose at least 2–3hrs before bedtime). Discard inhaler and replace after 7 days of use.
Failure to pass the Bronchitol Tolerance Test (BTT).
Must be administered under the supervision of a healthcare provider. Have rescue medication and resuscitation equipment readily available. Discontinue immediately if bronchospasm occurs; treat with an inhaled short-acting bronchodilator or as appropriate. History of significant hemoptysis episodes (>60mL) in the previous 3 months: not studied. Renal impairment. Pregnancy. Nursing mothers.
Cough, hemoptysis (discontinue if occurs), oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, arthralgia; bronchospasm.
Generic Drug Availability:
Caps—10, 140, 560 (w. inhalers)